🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: RPV 25 mg

Found 43 matching trials

Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)

PHASE4

The goal of this clinical study is to learn how safe it is to switch to an ...

Status

Completed

Location

Franco Felizarta, MD

Start Date

2023-12-13

Trial ID

NCT06104306

Treatments Being Tested

B/F/TAF

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

PHASE3

The primary objective of this study is to evaluate the efficacy of switchin...

Status

Completed

Location

University of Alabama at Birmingham

Start Date

2018-08-28

Trial ID

NCT03631732

Treatments Being Tested

B/F/TAF NRTIs Third Agent

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

PHASE3

This Antiretroviral Therapy as Long Acting Suppression every 2 Months (ATLA...

Status

Active Not Recruiting

Location

GSK Investigational Site

Start Date

2017-10-27

Trial ID

NCT03299049

Treatments Being Tested

Cabotegravir Tablets Rilpivirine Tablets Cabotegravir Injectable Suspension Rilpivirine Injectable Suspension

Pharmacokinetic Interactions of ENG Subdermal Implants with Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA)

PHASE4

The purpose of this pharmacokinetic (PK) trial is to evaluate whether the E...

Status

Withdrawn

Location

Multiple Locations

Start Date

2024-01-01

Trial ID

NCT05156658

Treatments Being Tested

Etonogestrel (ENG) Subdermal Implants

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

PHASE3

The primary objective of this study is to evaluate the non-inferiority of s...

Status

Completed

Location

Maricopa Integrated Health System

Start Date

2015-01-26

Trial ID

NCT02345226

Treatments Being Tested

FTC/RPV/TAF EFV/FTC/TDF Placebo EFV/FTC/TDF FTC/RPV/TAF Placebo

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

PHASE1

Treatment of human immunodeficiency virus (HIV) infection requires daily or...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-02

Trial ID

NCT02373930

Treatments Being Tested

DTG 50 mg RPV 25 mg DTG/RPV 50 mg/25 mg: Product Code AS DTG/RPV 50 mg/25 mg: Product Code AM DTG/RPV 50 mg/25 mg: Product Code AQ DTG/RPV 50 mg/25 mg: Product Code AK DTG/RPV 50 mg/25 mg: Product Code AR

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

PHASE2

This study is a Phase IIb, randomized, multicentre, parallel group, open-la...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-04-28

Trial ID

NCT02120352

Treatments Being Tested

CAB Oral Tablets CAB LA ABC/3TC Oral tablets RPV Oral Tablets HAART RPV

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

PHASE3

The purpose of this randomized, open-label, multicenter, active-controlled ...

Status

Completed

Location

University of Alabama - Birmingham

Start Date

2010-11

Trial ID

NCT01252940

Treatments Being Tested

FTC/RPV/TDF PI RTV NRTIs

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

PHASE3

This study will evaluate the efficacy of switching from emtricitabine/tenof...

Status

Completed

Location

University of Alabama at Birmingham

Start Date

2014-05-06

Trial ID

NCT02121795

Treatments Being Tested

FTC/TDF F/TAF Allowed third antiretroviral agent FTC/TDF Placebo F/TAF Placebo

Relative Bioavailability of Three Oral Formulations Candidates of Rilpivirine for Potential Pediatric Use Compared to Oral Tablet

PHASE1

The purpose of this study is to compare the rate and extent of absorption o...

Status

Completed

Location

Multiple Locations

Start Date

2015-10

Trial ID

NCT02561936

Treatments Being Tested

Rilpivirine Oral Tablet Rilpivirine formulation G007 Rilpivirine formulation G009-01 Rilpivirine formulation G002 Standardized Breakfast

Previous Next